Phenotypic characterization and prognostic impact of circulating γδ and αβ T-cells in metastatic malignant melanoma

International Journal of Cancer

Volumn 138, Issue 3, 2016, Pages 698-704

  Wistuba Hamprecht, Kilian ^a   Di Benedetto, Svetlana ^a   Schilling, Bastian ^b   Sucker, Antje ^b   Schadendorf, Dirk ^b   Garbe, Claus ^a   Weide, Benjamin ^a,c   Pawelec, Graham ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

biomarker; malignant melanoma; survival; T cells

Indexed keywords

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CD4+ ALPHA BETA T CELL; CD8+ ALPHA BETA T CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; LYMPHOCYTE DIFFERENTIATION; MALE; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PHENOTYPE; PROGNOSIS;

LYMPHOCYTE ANTIGEN RECEPTOR;

FEMALE; HUMANS; IMMUNOLOGIC MEMORY; MALE; MELANOMA; MIDDLE AGED; PHENOTYPE; PROGNOSIS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA;

EID: 84955672526     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29818     Document Type: Article

References (50)

1. Robert C, Karaszewska B, Schachter J, et al., Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 15: 30-9.
2. Hodi FS, O'Day SJ, McDermott DF, et al., Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
3. Weide B, Zelba H, Derhovanessian E, et al., Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol 2012; 1835-41.
4. Weide B, Martens A, Zelba H, et al., Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res 2014; 20: 1601-9.
5. Powell DJ, Jr., Dudley ME, Robbins PF, et al., Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 2005; 105: 241-50.
6. Hernberg M, Muhonen T, Turunen JP, et al., The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy. J Clin Oncol 1996; 14: 1690-6.
7. Saito H, Kranz DM, Takagaki Y, et al., Complete primary structure of a heterodimeric T-cell receptor deduced from cDNA sequences. Nature 1984; 309: 757-62.
8. Hayday AC, Saito H, Gillies SD, et al., Structure, organization, and somatic rearrangement of T cell gamma genes. Cell 1985; 40: 259-69.
9. Born W, Miles C, White J, et al., Peptide sequences of T-cell receptor delta and gamma chains are identical to predicted X and gamma proteins. Nature 1987; 330: 572-4.
10. Loh EY, Lanier LL, Turck CW, et al., Identification and sequence of a fourth human T cell antigen receptor chain. Nature 1987; 330: 569-72.
11. Hayday AC., [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 2000; 18: 975-1026.
12. Kang N, Tang L, Li X, et al., Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human. Immunol Lett 2009; 125: 105-13.
13. Casetti R, Agrati C, Wallace M, et al., Cutting edge: TGF-beta1 and IL-15 Induce FOXP3+ gammadelta regulatory T cells in the presence of antigen stimulation. J Immunol 2009; 183: 3574-7.
14. Kuhl AA, Pawlowski NN, Grollich K, et al., Human peripheral gammadelta T cells possess regulatory potential. Immunology 2009; 128: 580-8.
15. Kabelitz D, Peters C, Wesch D, et al., Regulatory functions of gammadelta T cells. Int Immunopharmacol 2013; 16: 382-7.
16. Wesch D, Peters C, Siegers GM., Human gamma delta T regulatory cells in cancer: fact or fiction? Front Immunol 2014; 5: 598.
17. Peters C, Oberg HH, Kabelitz D, et al., Phenotype and regulation of immunosuppressive Vdelta2-expressing gammadelta T cells. Cell Mol Life Sci 2014; 71: 1943-60.
18. Holtmeier W, Kabelitz D., gammadelta T cells link innate and adaptive immune responses. Chem Immunol Allergy 2005; 86: 151-83.
19. Beckman EM, Porcelli SA, Morita CT, et al., Recognition of a lipid antigen by CD1-restricted alpha beta+ T cells. Nature 1994; 372: 691-4.
20. De Libero G, Mori L., Self glycosphingolipids: new antigens recognized by autoreactive T lymphocytes. News Physiol Sci 2003; 18: 71-6.
21. Kjeldsen-Kragh J, Quayle AJ, Skalhegg BS, et al., Selective activation of resting human gamma delta T lymphocytes by interleukin-2. Eur J Immunol 1993; 23: 2092-9.
22. Fujimiya Y, Suzuki Y, Katakura R, et al., In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients. Clin Cancer Res 1997; 3: 633-43.
23. Ueta C, Kawasumi H, Fujiwara H, et al., Interleukin-12 activates human gamma delta T cells: synergistic effect of tumor necrosis factor-alpha. Eur J Immunol 1996; 26: 3066-73.
24. Begley M, Gahan CG, Kollas AK, et al., The interplay between classical and alternative isoprenoid biosynthesis controls gammadelta T cell bioactivity of Listeria monocytogenes. FEBS Lett 2004; 561: 99-104.
25. Eberl M, Hintz M, Reichenberg A, et al., Microbial isoprenoid biosynthesis and human gammadelta T cell activation. FEBS Lett 2003; 544: 4-10.
26. Bukowski JF, Morita CT, Brenner MB., Human gamma delta T cells recognize alkylamines derived from microbes, edible plants, and tea: implications for innate immunity. Immunity 1999; 11: 57-65.
27. Gober HJ, Kistowska M, Angman L, et al., Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003; 197: 163-8.
28. Thompson K, Rogers MJ., Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro. J Bone Miner Res 2004; 19: 278-88.
29. Wilhelm M, Kunzmann V, Eckstein S, et al., Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003; 102: 200-6.
30. Dieli F, Vermijlen D, Fulfaro F, et al., Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007; 67: 7450-7.
31. Argentati K, Re F, Serresi S, et al., Reduced number and impaired function of circulating gamma delta T cells in patients with cutaneous primary melanoma. J Invest Dermatol 2003; 120: 829-34.
32. Petrini I, Pacini S, Galimberti S, et al., Impaired function of gamma-delta lymphocytes in melanoma patients. Eur J Clin Invest 2011; 41: 1186-94.
33. Witherden DA, Havran WL., EPCR: a stress trigger for gammadelta T cells. Nat Immunol 2012; 13: 812-4.
34. Groh V, Steinle A, Bauer S, et al., Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 1998; 279: 1737-40.
35. Spada FM, Grant EP, Peters PJ, et al., Self-recognition of CD1 by gamma/delta T cells: implications for innate immunity. J Exp Med 2000; 191: 937-48.
36. Groh V, Rhinehart R, Secrist H, et al., Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999; 96: 6879-84.
37. Ferrarini M, Heltai S, Chiesa G, et al., V delta 1+ gamma/delta T lymphocytes Infiltrating human lung cancer express the CD8 alpha/alpha homodimer. Scand J Immunol 1994; 40: 363-7.
38. Zocchi MR, Ferrarini M, Migone N, et al., Tcell receptor V delta gene usage by tumour reactive gamma delta T lymphocytes infiltrating human lung cancer. Immunology 1994; 81: 234-9.
39. Maeurer MJ, Martin D, Walter W, et al., Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin. J Exp Med 1996; 183: 1681-96.
40. Choudhary A, Davodeau F, Moreau A, et al., Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma. J Immunol 1995; 154: 3932-40.
41. Devaud C, Rousseau B, Netzer S, et al., Anti-metastatic potential of human Vdelta1(+) gammadelta T cells in an orthotopic mouse xenograft model of colon carcinoma. Cancer Immunol Immunother 2013; 62: 1199-210.
42. Bauer S, Groh V, Wu J, et al., Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727-9.
43. Ferrarini M, Ferrero E, Dagna L, et al., Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol 2002; 23: 14-8.
44. Bialasiewicz AA, Ma JX, Richard G., Alpha/beta- and gamma/delta TCR(+) lymphocyte infiltration in necrotising choroidal melanomas. Br J Ophthalmol 1999; 83: 1069-73.
45. Balch CM, Gershenwald JE, Soong SJ, et al., Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-206.
46. Wistuba-Hamprecht K, Pawelec G, Derhovanessian E., OMIP-020: Phenotypic characterization of human gammadelta T-cells by multicolor flow cytometry. Cytometry A 2014; 85: 522-24.
47. Rosenberg SA, Yang JC, Sherry RM, et al., Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17: 4550-7.
48. Peng G, Wang HY, Peng W, et al., Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 2007; 27: 334-48.
49. Uchida R, Ashihara E, Sato K, et al., Gamma delta T cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surface. Biochem Biophys Res Commun 2007; 354: 613-8.
50. Gogoi D, Chiplunkar SV., Targeting gamma delta T cells for cancer immunotherapy: bench to bedside. Indian J Med Res 2013; 138: 755-61.